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a Regenerative Medicine Programme, Institut d’Investigació Biomèdica de Bellvitge, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain 
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A B S T R A C T   
Skin fibroblasts were obtained from four patients with 7q11.23 microduplication syndrome carrying the reciprocal rearrangement of Williams-Beuren syndrome at 
the 7q11.23 genomic region. Induced pluripotent stem cells (iPSCs) were generated by retroviral infection of fibroblasts with polycystronic vectors. The generated 
iPSC clones ESi058B, ESi057B, ESi070A and ESi071A had the 7q11.23 duplication with no additional genomic alterations, a stable karyotype, expressed pluripotency 
markers and could differentiate towards the three germ layers in vitro via embryoid body formation and in vivo by teratoma formation. Patient’s derived iPSCs are a 
valuable resource for in vitro modeling of 7q11.23 microduplication syndrome. 
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Alternative names of 
stem cell lines 
DUP7 FiPS4 R4F-2, 4.2 (ESi058B) 
DUPSW FiPS301 R4F-1, 301.1 (ESi057B) 
DUPSW FiPS501 R4F-2, 501.2 (ESi070A) 
DUPSW FiPS701 R4F-6, 701.6 (ESi071A) 
Institution Regenerative Medicine Programme, Institut 
d’Investigació Biomèdica de Bellvitge, IDIBELL, 
L’Hospitalet de Llobregat, Barcelona, Spain 
Centro de Investigación Biomédica en Red (CIBERER and 
CIBER-BBN). Universitat Pompeu Fabra. Barcelona. 
Institució Catalana de Recerca I Estudis Avançats 
(ICREA). Universitat de Barcelona 
Contact information of 
distributor 
Anna Veiga: aveiga@idibell.cat 
Roser Corominas: rosercorominas@ub.edu 
Type of cell lines iPSC 
Origin Human (Table 1) 
Cell Source Skin fibroblasts 
Retrovirus (OCT4, SOX2, KLF4, MYC) 




Multiline rationale Same disease, different patients 
Gene modification Yes 
Type of modification De novo formation 
Associated disease 7q11.23 microduplication syndrome, ORPHA 96121 
Gene/locus 7q11.23 duplication [hg19]7q11.23(72.7–74.2 Mb)x3 
Method of modification Duplication 
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(Comité de Ética e Investigación Clinica-CEIC-CMRB) 
and by the Catalan Authority for Stem Cell Research 
(Approval number: 05/2011) 
* Corresponding author. 
E-mail address: rosercorominas@ub.edu (R. Corominas).  
Contents lists available at ScienceDirect 
Stem Cell Research 
journal homepage: www.elsevier.com/locate/scr 
https://doi.org/10.1016/j.scr.2020.102092 
Received 1 October 2020; Received in revised form 3 November 2020; Accepted 15 November 2020   
Stem Cell Research 49 (2020) 102092
2
1. Resource utility 
7q11.23 microduplication syndrome (DUPSW) is a multisystemic 
neurodevelopmental disorder caused by ~ 1.5–1.8 Mb duplications at 
chromosome 7q11.23, encompassing 26–28 genes (Somerville et al., 
2005). Patients present speech disorders, behavioral problems and 
developmental delay, among others. The availability of iPSCs facilitates 
the study of functional mechanisms, as those occurring during devel-
opment or in inaccessible tissues. 
2. Resource details 
The iPS lines were generated from fibroblasts derived from skin bi-
opsies obtained from patients suffering 7q11.23 microduplication syn-
drome, the reciprocal rearrangement of Williams-Beuren Syndrome. 
Three patients carry the typical 1.5 Mb hemizygous duplication at 
chromosome 7q11.23 (Table 1) and DUPSW FiPS501 R4F-2 carries a 2 
Mb duplication. DUPSW is a rare genetic neurodevelopmental disorder 
[ORPHA 96121] caused by a heterozygous duplication of multiple 
contiguous genes at 7q11.23 (Somerville et al., 2005). The clinical 
characteristics of the patients include, intellectual disability, macro-
cephaly, dysmorphology, bilateral hearing loss and labial palate cleft 
(DUPSW FiPS301 R4F-1); intellectual disability, language delay, anxi-
ety, attention-deficit/hyperactivity disorder (ADHD) and obsessive 
compulsive symptomatology, mitochondrial cytopathy, nistagmus, and 
mild tricuspid insufficiency (DUP7 FiPS4 R4F-2); language and devel-
opmental delay, behavioral problems (including autism spectrum dis-
orders (ASD)), cryptorchidism, bilateral rectum paresis, constipation, 
dentation alterations, in addition to congenital cataracts and discrete 
tetraventricular hydrocephaly (DUPSW FiPS501 R4F-2); language and 
mild developmental delay with learning difficulties and behavioral 
problems within the board ASD spectrum, ADHD, anxiety, and occa-
sional aggression (DUPSW FiPS701 R4F-6). The duplications had 
occurred de novo in the maternal (DUPSW FiPS301 R4F-1, DUPSW 
FiPS701 R4F-6) or paternal (DUP7 FiPS4 R4F-2, DUPSW FiPS501 R4F-2) 
chromosomes and were confirmed by molecular karyotype (Fig. 1A), 
MLPA and microsatellite analysis (Bayés et al., 2003). Except for DUPSW 
FiPS501 R4F-2, the origin of these rearrangements was probably 
mediated by the presence of a paracentric inversion in one of the 
parental chromosomes. Table 2. 
Skin derived fibroblasts were reprogrammed using two polycystronic 
retroviruses encoding the four factors (pMXs-OCT4-VP16-SOX2-mOr-
ange; pMXs-KLF4-MYC-GFP). The morphology of the colonies was the 
typical of iPSCs (Fig. 1B). Integration of retroviruses (Supplementary 
Fig. S1B) and silencing of retroviruses (Supplementary Fig. S1C) were 
determined by PCR and quantitative RT-PCR (qRT-PCR) using specific 
primers (Table 3). The pluripotency of the DUPSW iPSC lines was 
confirmed by immunofluorescence analysis of the pluripotency- 
associated markers OCT4, SOX2, NANOG, TRA-1–60, TRA-1–81, 
SSEA-3 and SSEA-4 (Fig. 1B, scale bars 50 µm), the mRNA expression of 
endogenous human factors OCT4, SOX2, KLF4 and c-MYC in comparison 
to control iPSC lines (hPSCreg: ESi045D and ESi045D), (Fig. 1C) and 
alkaline phosphatase (AP) activity (Supplementary Fig. S1E). The ca-
pacity of in vitro and in vivo differentiation towards the three germ layers 
was determined by embryoid body (EB) formation and differentiation 
and teratoma formation, respectively, followed by immunofluorescence- 
based detection of the definite endoderm markers α-fetoprotein (AFP) 
and forkhead box A2 (FOXA2), ectodermal markers βIII-tubulin (TUJ1), 
glial fibrillary acidic protein (GFAP) and neurofilament, and meso-
dermal markers α-smooth muscle actin (ASMA) and α-sarcomeric actin 
(ASA) (Fig. 1D and 1E, scale bars 50 µm). The normal 46, XX or 46, XY 
karyotypes of the iPSC lines were confirmed by G-banding analysis 
(Supplementary Fig. S1A). The genomic integrity of the iPSC lines and 
presence of the 1.5 or 2 Mb 7q11.23 duplication was confirmed by SNP- 
array (Fig. 1A) and the iPSC identity was confirmed by short tandem 
repeat analysis and compared with the patientś fibroblasts (Supple-
mentary Table S1). 
3. Materials and methods 
3.1. Reprogramming and cell culture conditions 
Skin derived fibroblasts at passage 4 were used for reprogramming 
by retroviral delivery. Retroviruses were produced in Phoenix Ampho-
trophic cells following transfection with pMX-OCT4_Flag-VP16-PTV- 
Sox2_HA-Orange or pMX-KLF4-cMYC-GFP polycistronic vectors. Retro-
virus containing medium was collected 48 h post-transfection, filtered 
(0.45 μm), supplemented with Polybrene (4 μg/ml) and used to trans-
duce 1x105 cells by spin infection. After 3 days, transduced fibroblasts 
were trypsinized, seeded onto irradiated human foreskin fibroblasts in 
HES medium (Knockout DMEM supplemented with 20% Knockout 
serum replacement, 2 mM Glutamax, 1% Penicillin-Streptomycin (P-S), 
0.1 mM β-mercaptoethanol, Gibco), 1% NEAA and 10 ng/ml bFGF 
(Millipore)) and incubated in a humified incubator at 37 ◦C and 5% CO2. 
Appearing iPSC colonies were manually picked for expansion. From 
passage 5 on, clones were changed to feeder-free conditions on matrigel 
(Corning) coated plates and mTSeR1 medium (StemCell Technologies). 
Passages were performed by incubating iPSC colonies with 0.5 mM 
EDTA for 2 min and cell clumps were generated by flushing colonies 
with a P1000 automatic pipette. 
3.2. PCR and quantitative RT-PCR 
For integration analysis, genomic iPSC DNA was isolated (Qiagen). 
Standard PCR was performed using BioTaq Polymerase (Table 3) and 
visualized in 1.5% agarose gel, using fibroblasts as negative control. 
For silencing analysis, total RNA was isolated following standard 
Trizol-based procedure. 1 μg of RNA was used for reverse transcription 
(SuperScript-II, Thermo-Fisher Scientific). The qRT-PCR was performed 
using Power SYBR Green PCR Master Mix in an ABIPrism 7900 ther-
mocycler (Applied Biosystems). Ct values were normalized with GAPDH 
as housekeeping gene and data analyzed with 2-ΔΔCt method. mRNA 
expression levels of virus derived transOCT4/SOX2 and transKLF4/ 
cMyc and endogenous pluripotency markers OCT4, SOX2, KLF4 and c- 
MYC were analyzed (Supplementary Fig. S1C and Fig. 1C). 
3.3. Karyotyping and AP staining 
Genomic integrity was confirmed by G-banded metaphase karyotype 
(Ambar, Barcelona). Briefly, 70% confluent feeder-free iPSC colonies 
were treated with colcemid (KaryoMax, Invitrogen), trypsinized, 
Table 1 
Summary of lines.  
iPSC line names Abbreviation in figures Gender Age Ethnicity Genotype of locus Disease 
DUP7 FiPS4 R4F-2 (ESi058B)  4.2 Female 13 Caucasian Duplication 7q11.23 microduplication syndrome 
DUPSW FiPS301 R4F-1 (ESi057B)  301.1 Female 15 Caucasian Duplication 7q11.23 microduplication syndrome 
DUPSW FiPS501 R4F-2 (ESi070A)  501.2 Male 17 Caucasian Duplication 7q11.23 microduplication syndrome 
DUPSW FiPS701 R4F-6 (ESi071A)  701.6 Male 4 Caucasian Duplication 7q11.23 microduplication syndrome  
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Fig.1. Characterization of DUPSW iPSC lines. A. SNP-arrays of lines showing the presence of the 1.5 Mb 7q11.23 duplication. B. Confocal images showing 
immunodetection of pluripotency markers. Scale bars: 50 µm. Phase contrast pictures (right column, scale bars: 100 µm) showing morphology of iPSC clones. C. 
mRNA expression levels of endogenous pluripotency markers in comparison to control iPSC lines ESi044-D and ESi045-D. 2-ΔΔCt values normalized to GAPDH. D. In 
vitro differentiation of embryoid bodies using specific antibodies against the endodermal markers α-fetoprotein (AFP) and forkhead box A2 (FOXA2), ectodermal 
markers βIII-tubulin (TUJ1) and Glial fibrillary acidic protein (GFAP) and mesodermal marker α-smooth muscle actin (ASMA) and α-sarcomeric actin (ASA). Nuclei 
were stained with DAPI. Scale bars: 50 µm. E. In vivo differentiation and teratoma formation using specific antibodies against the endodermal markers AFP and 
FOXA2, ectodermal markers TUJ1, GFAP and Neurofilament and mesodermal marker ASMA and ASA. Nuclei were stained with DAPI. Scale bars: 50 µm. 
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incubated with hypotonic solution and fixed in Carnoy fixative (75% 
methanol, 25% acetic acid). 
To detect AP activity, iPSCs were fixed with 4% paraformaldehyde 
(PFA) for 1 min, PBS washed and incubated with AP staining solution 
(Sigma) until colonies turned blue. 
3.4. Immunocytological staining 
To identify pluripotency markers, immunocytochemistry was per-
formed (Martí et al., 2013). iPSCs were fixed with 4% PFA, blocked and 
permeabilized with TBS + 0.5% Triton X-100 + 6% donkey serum. 
Primary antibodies (Table 3) were incubated overnight in TBS + 0.1% 
Triton X-100 + 6% donkey serum. Secondary antibodies (Table 3) were 
incubated for 2 h at 37 ◦C. Nuclei were stained with 4′,6-diamino-2- 
Table 2 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography Normal Fig. 1 panel B 
Phenotype Immunocytochemisty OCT4, SOX2, 
NANOG, TRA- 
1–60, TRA-1–81, 
SSEA-3 and SSEA- 
4 
Fig. 1 panel B 









Fig. 1 panel C 
Supplementary 
Fig. S1 panel C 
Integration PCR Integration of 
retroviral OCT4, 
SOX2, KLF4 and 
c-MYC 
Supplementary 
Fig. S1 panel B 
AP staining positive Supplementary 
Fig. S1 panel E 












Fig. S1 panel A 





















testing by PCR: 
Negative 
Supplementary 

















Fig. 1 panel D 









N/A N/A N/A  
Table 3 
Reagents details.  
Antibodies used for immunocytochemistry/flow-citometry  




Mouse anti-OCT4 1:25 Santa Cruz, sc-5279, 
RRID:AB_628051 
Goat anti-NANOG 1:25 R&D Systems, AF1997, 
RRID:AB_355097 
Rabbit anti-SOX2 0.1111 ABR, PA1-16968, RRID: 
AB_2195781 
Rat anti-SSEA3 1:02 Hybridoma Bank, MC- 
631, RRID:AB_528476 













Mouse anti-TUJ1 1:40 Covance, MMS-435P, 
RRID:AB_2313773 




0.1111 Sigma N4142, RRID: 
AB_477272 
Mouse anti-ASMA 0.3194 Sigma, A5228, RRID: 
AB_262054 
Mouse anti-ASA 0.3194 Sigma, A2172, RRID: 
AB_476695 
Rabbit anti-AFP 0.1806 Agilent, A0008, RRID: 
AB_2650473 




488 Donkey Anti- 
Mouse 
0.1806 Jackson, 715–545-151, 
RRID:AB_2341099 
488 Goat Anti- 
Mouse 
0.1806 Jackson, 115–546-071, 
RRID:AB_2338865 
488 Donkey Anti- 
Rabbit 




0.1806 Jackson, 711–475-152, 
RRID:AB_2340616 
Cy™3 Donkey Anti- 
Mouse 
0.1806 Jackson, 715–165-140, 
RRID:AB_2340812 
Cy™3 Donkey Anti- 
Goat 
0.1806 Jackson, 705–165-147, 
RRID:AB_2307351  
Primers  
Target Forward/Reverse primer (5′-3′) 
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fenilindol (Martí et al., 2013). 
3.5. In vitro and in vivo differentiation 
In vitro differentiation was promoted by EB formation. iPSCs colonies 
were lifted manually and incubated in ultra-low attachment plates in 
mTeSR1 medium. After 24 h, medium was changed to differentiation 
medium for additional 24–48 h (Ectoderm: 50% Neurobasal medium, 
50% DMEM/F12, 1% N2, 1% B27, 1% Glutamax and 1% P-S; Endoderm: 
Knockout-DMEM, 10% FBS-Hyclone, 1% NEAA, 0.1% β-mercaptoetha-
nol, 1% Glutamax and 1% P-S; Mesoderm: Endoderm medium supple-
mented with 0.5 mM ascorbic acid). EBs were seeded on matrigel-coated 
slide flasks and cultured in differentiation media for 15–20 days, then 
analyzed by immunocytochemistry as described. Confocal images were 
taken using Leica TSC SPE or Leica SP5 microscopes. 
In vivo differentiation was induced by intratesticular injection of 
0.5x106 iPSCs into severe combined immunodeficient (SCID) mice. After 
8 weeks of growth, teratomas were extracted, PFA-fixed, paraffin 
embedded and analyzed by immunocytochemistry. 
3.6. Confirmation of microduplications and STR analysis 
7q11.23 microduplications and the absence of novel rearrangements 
were confirmed by SNP-array (Illumina Infinium HumanCore-24, 
IMPPC) using 0.5 µg of iPSC genomic DNA. Line identities were 
corroborated by genotyping (STRs-study). 
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